This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Somlo, G. Articles by Doroshow, J. H. Search for Related Content PubMed PubMed Citation Articles by Somlo, G. Articles by Doroshow, J. H. Social Bookmarking                            What's this?

Prognostic Indicators and Survival in Patients With Stage IIIB Inflammatory Breast Carcinoma After Dose-Intense Chemotherapy

From the Departments of Medical Oncology and Therapeutics Research, Biostatistics, Hematology/Bone Marrow Transplantation, and Anatomic Pathology, City of Hope Comprehensive Cancer Center, Duarte; Kaiser Permanente Southern California, Los Angeles; and University of California San Francisco, San Francisco, CA; and The Good Samaritan Bone Marrow Transplant Unit, Phoenix, AZ.

Address reprint requests to George Somlo, MD, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010; e-mail: gsomlo{at}coh.org

PURPOSE: To improve treatment outcome for patients presenting with inflammatory breast cancer (IBC), we have sequentially developed and tested single and tandem dose-intense chemotherapy regimens (DICT). Tumor- and treatment-related factors were analyzed to generate a prognostic model.

PATIENTS AND METHODS: Between May 1989 and April 2002, 120 patients received conventional-dose chemotherapy, surgery, and sequentially developed single- or tandem-cycle DICT. Disease- and treatment-specific features were subjected to univariate and multivariate analysis to correlate with outcome.

RESULTS: At a median follow-up of 61 months (range, 21 to 161 months), estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 44% (95% CI, 34% to 53%) and 64% (95% CI, 55% to 73%), respectively. In an age-adjusted multivariate analysis, RFS was better in patients with estrogen receptor (ER)/progesterone receptor (PR)–positive tumors (P = .002), for patients with fewer than four involved axillary nodes before DICT (P = .01), and in patients treated with radiation therapy (P = .001) and tandem DICT (P = .049). OS was improved in patients with ER/PR-positive tumors (P = .002), in those with fewer than four involved axillary nodes before DICT (P = .03), and in patients treated with radiation therapy (P = .002).

CONCLUSION: This retrospective analysis suggests that either single or tandem DICT can be administered safely and may benefit selected patients with stage IIIB IBC. Those with receptor-negative IBC and with four or more involved axillary nodes before DICT need improved neoadjuvant and postadjuvant intensification therapy. A prospective randomized trial of single versus tandem DICT would be required to confirm the potential benefit of tandem DICT in the setting of IBC.

Supported by grant Nos. CA 33572 and CA 62505 from the National Cancer Institute, a General Research Center grant from the National Institutes of Health (grant No. M01 RR00043), Bethesda, MD, and an unrestricted grant from Bristol-Myers and Squibb Co, Princeton, NJ.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Somlo, P. Chu, P. Frankel, W. Ye, S. Groshen, J. H. Doroshow, K. Danenberg, and P. Danenberg Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome Ann. Onc., November 1, 2008; 19(11): 1853 - 1859. [Abstract] [Full Text] [PDF]

				S. I. Labidi, K. Mrad, A. Mezlini, M. A. Ouarda, J. D. Combes, M. B. Abdallah, K. B. Romdhane, P. Viens, and F. B. Ayed Inflammatory breast cancer in Tunisia in the era of multimodality therapy Ann. Onc., March 1, 2008; 19(3): 473 - 480. [Abstract] [Full Text] [PDF]

				R. L. Smoot, C. A. Koch, A. C. Degnim, S. Sterioff, J. H. Donohue, C. S. Grant, S. A. Barnes, R. E. Gullerud, T. J. Hobday, and D. R. Farley A Single-Center Experience With Inflammatory Breast Cancer, 1985-2003 Arch Surg, June 1, 2006; 141(6): 567 - 573. [Abstract] [Full Text] [PDF]

				K. W. Hance, W. F. Anderson, S. S. Devesa, H. A. Young, and P. H. Levine Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute J Natl Cancer Inst, July 6, 2005; 97(13): 966 - 975. [Abstract] [Full Text] [PDF]

				A. M. Gonzalez-Angulo, P. Morandi, and M. Cristofanilli Inflammatory Breast Cancer and High-Dose Chemotherapy: Back to the Past J. Clin. Oncol., June 1, 2005; 23(16): 3859 - 3860. [Full Text] [PDF]

				G. Somlo In Reply: J. Clin. Oncol., June 1, 2005; 23(16): 3860 - 3862. [Full Text] [PDF]